Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents

Tuberculosis (TB) remains a challenging global health concern and claims more than a million lives every year. We lack an effective vaccine and understanding of what constitutes protective immunity against TB to inform rational vaccine design. Moreover, treatment of TB requires prolonged use of multi-drug regimens and is complicated by problems of compliance and drug resistance. While most (Mtb) bacilli are quickly killed by the drugs, the prolonged course of treatment is required to clear persistent drug-tolerant subpopulations. Mtb's differential sensitivity to drugs is, at least in part, determined by the interaction between the bacilli and different host macrophage populations. Therefore, to design better treatment regimens for TB, we need to understand and modulate the heterogeneity and divergent responses that Mtb bacilli exhibit within macrophages. However, developing drugs is a long and expensive process. An alternative approach to expedite the development of new TB treatments is to repurpose existing drugs that were developed for other therapeutic purposes if they also possess anti-tuberculosis activity. There is growing interest in the use of immune modulators to supplement current anti-TB drugs by enhancing the host's antimycobacterial responses. Ion channel blocking agents are among the most promising of the host-directed therapeutics. Some ion channel blockers also interfere with the activity of mycobacterial efflux pumps. In this review, we discuss some of the ion channel blockers that have shown promise as potential anti-TB agents

Differential localization and limited cytotoxic potential of duodenal CD8+Tcells

The duodenum is a major site of HIV persistence during suppressive antiretroviral therapy despite harboring abundant tissue-resident memory (Trm) CD8(+) T cells. The role of duodenal Trm CD8(+) T cells in viral control is still not well defined. We examined the spatial localization, phenotype, and function of CD8(+) T cells in the human duodenal tissue from people living with HIV (PLHIV) and healthy controls. We found that Trm (CD69(+)CD103(hi)) cells were the predominant CD8(+) T cell population in the duodenum. Immunofluorescence imaging of the duodenal tissue revealed that CD103(+)CD8(+) T cells were localized in the intraepithelial region, while CD103(–)CD8(+) T cells and CD4(+) T cells were mostly localized in the lamina propria (LP). Furthermore, HIV-specific CD8(+) T cells were enriched in the CD69(+)CD103(–/lo) population. However, the duodenal HIV-specific CD8(+) Trm cells rarely expressed canonical molecules for potent cytolytic function (perforin and granzyme B) but were more polyfunctional than those from peripheral blood. Taken together, our results show that duodenal CD8(+) Trm cells possess limited perforin-mediated cytolytic potential and are spatially separated from HIV-susceptible LP CD4(+) T cells. This could contribute to HIV persistence in the duodenum and provides critical information for the design of cure therapies